Additional file 1: Table S1. of Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement

Baseline characteristics of subjects prior to trimming. Table describing baseline characteristics of subjects prior to trimming. (DOCX 13 kb

Additional file 3: Table S2. of Drug safety analyses in a rheumatoid arthritis registry: application of different approaches regarding timing of exposure and confounder measurement

Balance of selected potential confounders by exposure group for quintiles in methods 7–13. (DOCX 15 kb

Additional file 1: of Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry

Table S1 describes the rates of remaining on drug, switching, and discontinuing without starting a new biologic in the TCZ and ABA groups before and after match. Table S2 presents the distribution of prednisone dose increases and decreases between the matched TCA and ABA initiators based on the baseline prednisone usage. Table S3 presents rates of discontinuation and initiation of cDMARDs over the 6-month follow-up. (DOCX 14 kb

Additional file 5: of Association between inflammation and systolic blood pressure in RA compared to patients without RA

Table S1. Association between change in C-reactive protein (CRP) (per 10 mg/L) and change in diastolic blood pressure (DBP), pulse pressure (PP), and mean arterial pressure (MAP) (per mmHg) in patients with rheumatoid arthritis with significant changes in inflammation. (DOCX 17 kb

Additional file 4: of Association between inflammation and systolic blood pressure in RA compared to patients without RA

Figure S4. The relationship between C-reactive protein levels (CRP) and systolic blood pressure with 95% confidence intervals, in the non-RA outpatient population and general population (NHANES) with trimming of extreme measurements of CRP (< 0.5% and > 99.5%). Non-RA outpatient population CRP range 0.10–142.20 mg/L; NHANES CRP range 0.02–4.22 mg/L. RA, rheumatoid arthritis; NHANES, National Health and Nutrition Examination Survey. (PDF 471 kb

Additional file 3: of Association between inflammation and systolic blood pressure in RA compared to patients without RA

Figure S3. The relationship between C-reactive protein levels (CRP) and systolic blood pressure with 95% confidence intervals, in the RA outpatient population and the general population (NHANES) with trimming of extreme measurements of CRP (< 0.5% and > 99.5%). RA outpatient population CRP range 0.20–92.40 mg/L; NHANES CRP range 0.02–4.22 mg/L. RA, rheumatoid arthritis; NHANES, National Health and Nutrition Examination Survey. (PDF 476 kb

Additional file 2: of Association between inflammation and systolic blood pressure in RA compared to patients without RA

Figure S2. The relationship between C-reactive protein levels (CRP) and diastolic blood pressure (A), pulse pressure (B), and mean arterial pressure (C) with 95% confidence intervals, in the non-RA outpatient population and the general population (NHANES). RA, rheumatoid arthritis; NHANES, National Health and Nutrition Examination Survey. (PDF 1361 kb